Inovio (INO) Bullish Stance Reiterated at Maxim Group Amid MERS Trial Patient Recruitment and Zika Vaccine Progress
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy reiterated his Buy rating and $14 price target on Inovio Pharmaceuticals (NASDAQ: INO) as MERS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
